Here’s the complete amfAR news release:
amfAR’s Countdown to a Cure for AIDS initiative received a major boost this fall thanks to a generous grant from the Campbell Foundation, which offered to match individual contributions dollar for dollar up to $50,000 during September and October. amfAR donors responded enthusiastically, with individual gifts totaling nearly $150,000. This means that the Campbell Foundation’s initial investment has yielded nearly $200,000 for our cure-focused research grants—enough to put a research team to work for two years.
The Campbell Foundation, a longtime HIV/AIDS research funder based in Florida, chose to support Countdown to a Cure in order to maintain the exciting momentum toward a cure that has energized the field in recent years. Launched earlier this year, Countdown to a Cure is aimed at developing the scientific basis for a cure for HIV by 2020. Over the past three decades, amfAR-funded research has led to numerous breakthroughs that have saved lives and helped us identify the final remaining obstacles standing between us and a cure for HIV.
Sign Up and Save
Get six months of free digital access to the Miami Herald
Now, by ramping up our investments in cutting-edge cure research, we are working to target and overcome these roadblocks, to achieve our ultimate goal of ending the epidemic in our lifetime. Contributions from our dedicated supporters—including the Campbell Foundation and the many individual donors who stepped up to give to the campaign—remain essential to this effort.
A leading funder of HIV/AIDS research since its founding in 1995 by the late Richard Campbell Zahn, the Campbell Foundation is a key amfAR partner, sharing our commitment to innovation and our willingness to support novel ideas.
More from the Campbell Foundation website:
The Campbell Foundation is committed to our original donor's intent of funding novel and groundbreaking laboratory-based HIV and AIDS research. Our funding includes various projects that aim to eradicate the HIV virus and curethe still-deadly infection.
The foundation's grant review process utilizes the evaluation services of a pro bono peer review board comprised of physicians and clinicians from throughout the United States. Our board of directors, who also serve pro bono, review a synopsis of each grant proposal for final funding decisions.
The Campbell Foundation was nationally recognized by Funders Concerned About AIDS, and is ranked in its top 60 of the 300 private philanthropic institutions supporting original HIV/AIDS research in the United States and Europe.
Why We Fund HIV/AIDS Research
HIV is different from other viruses due to its genetic variability – it replicates quickly, producing one thousand variations of the original virus every day, and it mutates daily.
Even when HIV is suppressed with a combination of the anti-viral drugs available, it hides in reservoirs of cells within the genital tract, lungs, lymphoid tissue, bone marrow and brain.
When a person stops taking a particular anti-HIV drug, HIV adapts and is no longer affected by it.
This is why on-going research is so important. We are fighting an evolving and elusive virus.
About Our Founder: Richard Campbell Zahn
Richard Zahn was a chemist who developed Herpecin-L Lip Balm for the treatment of cold sores and fever blisters. He established and operated Campbell Laboratories in Fort Lauderdale, FL, which manufactured and sold the lip balm.
In 1995, Mr. Zahn died from complications from AIDS. Herpecin-L was sold, and the proceeds flowed into the Campbell Foundation, which had a mandate to fund cutting-edge research to discover a cure for HIV.